NEW YORK (GenomeWeb News) – IntelliCell BioSciences today announced an exclusive agreement to sell and distribute EMD Millipore's Guava flow cytometry platform for stromal vascular fraction (SVF) applications.
IntelliCell manufactures SVF containing stem cells derived from fatty tissue. The deal streamlines the development of IntelliCell's tissue processing centers in the US, the New York-based company said.
The use of autologous stem cells has become widespread in the US and Europe, it added, and research is currently being conducted into the use of adipose stem cells for treating arthritis, orthopedic injuries, wound healing, congestive heart failure, gum regeneration, and other ailments.
Terms of the license were not disclosed.
Steven Victor, chairman and CEO of IntelliCell, said that the deal "combined with our proprietary process … gives us a highly significant advantage in creating the gold standard for the separation of SVF from fat."
EMD Millipore was formed following Merck KGaA's roughly $7 billion acquisition of Billerica, Mass.-based Millipore last year. Outside of the US and Canada the business operates under the name Merck Millipore.